Skip to main content
Premium Trial:

Request an Annual Quote

Certara Teams up with the Hamner Institutes for Health Sciences to Explore Liver Toxicity

Premium

Certara said this week that it is collaborating with the Hamner Institutes for Health Sciences to explore drug-induced liver toxicity.

Under the terms of the agreement signed by both parties, the partners will integrate the Hamner's drug-induced liver injury, DILI, modeling software into Certara's Simcyp simulator and test the integrated product's simulation capabilities with respect to drug exposure and resultant liver toxicity.

Brett Howell, lead scientist and manager of the DILI-simulation initiative at the Hamner, said that the collaborators aim to develop "a computer model that helps sponsors and regulators predict which drugs will produce DILI symptoms, and which subsets of the population are most likely to be affected."

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.